167 related articles for article (PubMed ID: 11372588)
21. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
Heinonen EH; Anttila MI; Karnani HL; Nyman LM; Vuorinen JA; Pyykkö KA; Lammintausta RA
J Clin Pharmacol; 1997 Jul; 37(7):602-9. PubMed ID: 9243353
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine.
Schmider J; Brockmöller J; Arold G; Bauer S; Roots I
Pharmacogenetics; 1999 Dec; 9(6):725-34. PubMed ID: 10634135
[TBL] [Abstract][Full Text] [Related]
23. Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.
Laine K; Anttila M; Helminen A; Karnani H; Huupponen R
Br J Clin Pharmacol; 1999 Mar; 47(3):249-54. PubMed ID: 10215747
[TBL] [Abstract][Full Text] [Related]
24. Bioavailability of two selegiline hydrochloride tablet products.
Müller FO; Schall R; Hundt HK; Joubert A; Middle MV; Muir AR; Duursema L; Groenewoud G; Swart KJ
Arzneimittelforschung; 1996 Nov; 46(11):1037-40. PubMed ID: 8955861
[TBL] [Abstract][Full Text] [Related]
25. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system.
Rohatagi S; Barrett JS; DeWitt KE; Lessard D; Morales RJ
Biopharm Drug Dispos; 1997 Nov; 18(8):665-80. PubMed ID: 9373724
[TBL] [Abstract][Full Text] [Related]
27. The CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of i.v. fentanyl.
Palkama VJ; Neuvonen PJ; Olkkola KT
Br J Anaesth; 1998 Oct; 81(4):598-600. PubMed ID: 9924238
[TBL] [Abstract][Full Text] [Related]
28. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
[TBL] [Abstract][Full Text] [Related]
29. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers.
Oda M; Kotegawa T; Tsutsumi K; Ohtani Y; Kuwatani K; Nakano S
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):615-9. PubMed ID: 14517708
[TBL] [Abstract][Full Text] [Related]
30. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects.
Park JY; Shon JH; Kim KA; Jung HJ; Shim JC; Yoon YR; Cha IJ; Shin JG
J Clin Psychopharmacol; 2006 Apr; 26(2):135-42. PubMed ID: 16633141
[TBL] [Abstract][Full Text] [Related]
31. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.
Varis T; Kaukonen KM; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Oct; 64(4):363-8. PubMed ID: 9797792
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo.
Dresser GK; Wacher V; Wong S; Wong HT; Bailey DG
Clin Pharmacol Ther; 2002 Sep; 72(3):247-55. PubMed ID: 12235445
[TBL] [Abstract][Full Text] [Related]
33. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice.
Siu EC; Tyndale RF
J Pharmacol Exp Ther; 2008 Mar; 324(3):992-9. PubMed ID: 18065502
[TBL] [Abstract][Full Text] [Related]
34. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin.
Kivistö KT; Kantola T; Neuvonen PJ
Br J Clin Pharmacol; 1998 Jul; 46(1):49-53. PubMed ID: 9690949
[TBL] [Abstract][Full Text] [Related]
35. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration.
Rohatagi S; Barrett JS; DeWitt KE; Morales RJ
Biopharm Drug Dispos; 1997 Oct; 18(7):567-84. PubMed ID: 9330778
[TBL] [Abstract][Full Text] [Related]
36. Effect of itraconazole on the pharmacokinetics of atorvastatin.
Kantola T; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Jul; 64(1):58-65. PubMed ID: 9695720
[TBL] [Abstract][Full Text] [Related]
37. Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine.
Isohanni MH; Neuvonen PJ; Olkkola KT
Pharmacol Toxicol; 1999 Mar; 84(3):143-6. PubMed ID: 10193676
[TBL] [Abstract][Full Text] [Related]
38. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
Niemi M; Backman JT; Juntti-Patinen L; Neuvonen M; Neuvonen PJ
Br J Clin Pharmacol; 2005 Aug; 60(2):208-17. PubMed ID: 16042675
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline.
Chen L; Shen B; Wang S; Yu Y; Yan H; Shi Y; Duan G; Xiang P
Drug Test Anal; 2019 Jun; 11(6):898-905. PubMed ID: 30614204
[TBL] [Abstract][Full Text] [Related]
40. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine.
Isohanni MH; Neuvonen PJ; Palkama VJ; Olkkola KT
Eur J Clin Pharmacol; 1998 Sep; 54(7):561-5. PubMed ID: 9832299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
